Skip to main content
Bulletin of the National Research Centre

Table 13 Newly designed parthenolide derivative compounds with their new predicted activities (pIC50)

From: QSAR, molecular docking studies, ligand-based design and pharmacokinetic analysis on Maternal Embryonic Leucine Zipper Kinase (MELK) inhibitors as potential anti-triple-negative breast cancer (MDA-MB-231 cell line) drug compounds

Back to article page